Betta Pharmaceuticals Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MCLA-129 NCT06885840 |
P2 | Not yet recruiting | Non-Small Cell Lung Cancer | 100 | 2028-04 |
| NCT06041776 NCT06041776 |
P3 | Recruiting | Non-Small Cell Lung Cancer; EGFR Sensitive Mutation | 570 | 2028-04-30 |
| MCLA-129 NCT04930432 |
P1/2 | Recruiting | Solid Tumor; Non-Small Cell Lung Cancer | 400 | 2028-04-30 (+46 mo) |
| Befotertinib NCT07181499 |
P2 | Recruiting | NSCLC; Adjuvant Drug Therapy | 28 | 2028-11 |
| BPI-572270 NCT07435038 |
P1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC) | 120 | 2028-12-28 |
| MCLA-129 NCT07448116 |
P1/2 | Recruiting | Solid Advanced Tumor | 164 | 2029-02-01 |